BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-15 out of 15 found
  Current Search:  pioglitazone: 15     

HTML
100%
A New Treatment Option For Adults With Type 2 Diabetes
THERE?S IMPORTANT NEWS FOR ADULTS WITH TYPE 2 DIABETES, THE FDA RECENTLY APPROVED A NEW MEDICINE.

DANIELLE ADDAIR HAS MORE.

STORY INFORMATION: THIS IS A MULTIVU SPECIAL REPORT BROUGHT TO YOU BY BRISTOL-MEYERS SQUIBB AND ASTRAZENECA.

DESPITE CURRENT...

MedicalNewsService.com:  Jan 16 2010 4:31AM
Matching: pioglitazone
Find similar documents
HTML
100%
Pioglitazone Compared with Metformin Increases Pericardial Fat Volume in Patients with Type 2 Diabetes Mellitu
The Journal of Clinical Endocrinology & Metabolism Jan 2010 Vol.

95, No.

1 456-460 J.

Jonker, H.

Lamb, R.

van der Meer, L.

Rijzewijk, L.

Menting, M.

Diamant, J.

Bax, A.

de Roos, J.

Romijn and J.

Smit Departments of Endocrinology and...

National AIDS Treatment Advocacy Project:  Jan 10 2010 2:20PM
Matching: pioglitazone
Find similar documents
HTML
100%
Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients
The Journal of Clinical Endocrinology & Metabolism 2002 Vol.

87, No.

6 2784-2791 Yoshinori Miyazaki, Archana Mahankali, Masafumi Matsuda, Srikanth Mahankali, Jean Hardies, Kenneth Cusi, Lawrence J.

Mandarino and Ralph A.

DeFronzo University of Texas...

National AIDS Treatment Advocacy Project:  Jan 10 2010 2:20PM
Matching: pioglitazone
Find similar documents
HTML
100%
Dr Reddy's: New molecule hopes
While the results of the clinical trials on the companys new molecule, Balaglitazone, are positive, a lot needs to be done.

The Dr Reddys stock surged about 4 per cent since the start of the week on announcements of encouraging Phase III trials of an anti...

Business Standard India:  Jan 8 2010 2:44AM
Matching: pioglitazone
Find similar documents
HTML
100%
Risk of death lower for pioglitazone and higher for sulphonylureas versus metformin, study suggests
Sulphonylureas are associated with a greater risk of heart failure and death than metformin, according to research published online in the BMJ (2009;339:b4731).

Researchers from Imperial College, London, retrospectively analysed data from over 90,000 diabetic...

PJ Online:  Jan 7 2010 8:52AM
Matching: pioglitazone
Find similar documents
HTML
100%
Diabetes Compound from Dr. Reddy's Found Successful in Phase III Study
India-based drug maker Dr.

Reddys Laboratories and a subsidiary of Nordic Bioscience, Rheoscience, announced the success of a diabetic compound from the first phase III study.

According to the study, their investigational agent, Balaglitazone, a diabetes...

MedIndia:  Jan 6 2010 3:33PM
Matching: pioglitazone
Find similar documents
HTML
100%
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Tzoulaki I et al.

The findings suggest a relatively unfavourable risk profile of sulphonylureas compared with metformin for all outcomes examined.

Pioglitazone was associated with reduced all cause mortality compared with metformin.

Risk of...

MDLinx:  Jan 6 2010 1:27PM
Matching: pioglitazone
Find similar documents
HTML
100%
Dr. Reddy's And Rheoscience Announce Headline Results From First Phase III Clinical Trial of Balaglitazone (DRF 2593)
Reddy's Laboratories Ltd.

(NYSE:RDY) and Rheoscience, a subsidiary of Nordic Bioscience A/S, today announced the headline results from the first phase III study for their investigational agent, Balaglitazone.

The study (Study 307) was a phase III,...

Pharmaceutical Online:  Jan 5 2010 10:41PM
Matching: pioglitazone
Find similar documents
HTML
100%
Dr. Reddy's and Rheoscience Announce Headline Results from First Phase III Clinical Trial of Balaglitazone (DR
Significant reduction in HbA1c with Balaglitazone and improved safety profile HYDERABAD, India--(BUSINESS WIRE)--Jan 4, 2010 - Dr.

Reddy's Laboratories Ltd.

(NYSE:RDY) and Rheoscience, a subsidiary of Nordic Bioscience A/S, today announced the headline...

Pharma Live:  Jan 5 2010 9:32PM
Matching: pioglitazone
Find similar documents
HTML
100%
Dr. Reddy's type-2 diabetes drug balaglitazone meets primary endpoint in phase III study
Dr Reddy's Laboratories Ltd and Rheoscience, a subsidiary of Nordic Bioscience A/S, announced the headline results from the first phase-III study for their investigational agent, Balaglitazone.

The study (Study 307) was a phase-III, randomized, double blind,...

PharmaBiz:  Jan 5 2010 9:10AM
Matching: pioglitazone
Find similar documents
HTML
100%
Dr Reddy's diabetes compound meets success
Hyderabad, India-based drug maker Dr Reddys Laboratories and Rheoscience, a subsidiary of Nordic Bioscience announced the headline results from the first phase III study for their investigational agent, Balaglitazone, a diabetes compound.

The study was a...

Bio Spectrum Asia:  Jan 5 2010 6:49AM
Matching: pioglitazone
Find similar documents
HTML
100%
Headline results from first phase III study of Balaglitazone announced
Reddys Laboratories Ltd.

(NYSE:RDY) and Rheoscience, a subsidiary of Nordic Bioscience A/S, today announced the headline results from the first phase III study for their investigational agent, Balaglitazone.

The study (Study 307) was a phase III, randomized...

News-Medical.Net:  Jan 5 2010 4:59AM
Matching: pioglitazone
Find similar documents
HTML
100%
Dr. Reddy's and Rheoscience Announce Headline Results from First Phase III Clinical Trial of Balaglitazone (DRF 2593)
HYDERABAD, India--(BUSINESS WIRE)--Dr.

Reddy?s Laboratories Ltd.

(NYSE: RDY) and Rheoscience, a subsidiary of Nordic Bioscience A/S, today announced the headline results from the first phase III study for their investigational agent, Balaglitazone.

The...

Yahoo! Canada:  Jan 4 2010 3:53PM
Matching: pioglitazone
Find similar documents
HTML
100%
Dr. Reddy's and Rheoscience Announce Headline Results from First Phase III Clinical Trial of Balaglitazone (DR
Reddys Laboratories Ltd.

(NYSE:RDY) and Rheoscience, a subsidiary of Nordic Bioscience A/S, today announced the headline results from the first phase III study for their investigational agent, Balaglitazone.

The study (Study 307) was a phase III, randomized...

Genetic Engineering News:  Jan 4 2010 3:49PM
Matching: pioglitazone
Find similar documents
HTML
100%
Takeda and Pfizer to Co-Promote Takeda's Actos (Pioglitazone HCl) for the Treatment of Type 2 Diabetes in Ch
- Takeda Pharmaceutical Company Limited (Takeda) and Pfizer Inc.

(Pfizer) announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda's Actos (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China.

The...

Pharma Live:  Dec 15 2009 3:24PM
Matching: pioglitazone
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.